AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2132179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.i.d. for 1 week followed by 40 mg b.i.d. for 3 weeks
Number of subjects: 221
Study 2132179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 221
Study 2132179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 2132179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin and Placebo
Number of subjects: 221
Study 620898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (15 mg)
Number of subjects: 22
Study 620898 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age-matched)
Number of subjects: 22
Study 31887225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1027
Study 31887225 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab
Number of subjects: 1027
Study 31542049 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular simple cubic configurations; magnetization oriented along a face or space diagonal of the cubic unit cell.
Number of subjects: 0
Study 31542049 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular simple cubic configurations; magnetization along the edge of the cubic unit cell.
Number of subjects: 0
Study 31542049 — intervention group
Group type: EXPERIMENTAL
Intervention: Body- and face-centered configurations; magnetization along a face or space diagonal of the unit cell.
Number of subjects: 0
Study 31542049 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized configurations; compressible systems.
Number of subjects: 0
Study 28093243 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 100
Study 28093243 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 26480547 — intervention group
Group type: COMPARATOR
Intervention: Western medication (estazolam 1mg before bed, oryzanol 20 mg three times a day) for 4 weeks
Number of subjects: 98
Study 26480547 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (at specific acupoints) for 4 weeks
Number of subjects: 98
Study 26480547 — intervention group
Group type: COMPARATOR
Intervention: Integrated acupuncture and medication (same as above) for 4 weeks
Number of subjects: 98
Study 23633132 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device treatment for MR reduction
Number of subjects: 64
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive strategies without WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive strategies with WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic strategies without WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic strategies with WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex GT with WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex GT without WM load
Number of subjects: 0
Study 20697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective expected utility measure
Number of subjects: 0
Study 19857626 — intervention group
Group type: EXPERIMENTAL
Intervention: HAES group
Number of subjects: 144
Study 19857626 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support group
Number of subjects: 144
Study 19857626 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 19857626 — intervention group
Group type: COMPARATOR
Intervention: HAES group vs Control group
Number of subjects: 144
Study 19857626 — intervention group
Group type: COMPARATOR
Intervention: Social support group vs Control group
Number of subjects: 144
Study 17214093 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen (CEE + MPA)
Number of subjects: 7529
Study 17214093 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous unopposed CEE
Number of subjects: 7529
Study 17214093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both estrogen treatments (CEE with or without MPA) pooled
Number of subjects: 7529
Study 17214093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 7529
Study 17214093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7529
Study 15342260 — intervention group
Group type: EXPERIMENTAL
Intervention: Learned encoding techniques acquired during nearly a thousand hours of practice memorizing the mathematical constant pi
Number of subjects: 1
Study 15342260 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 11316344 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite
Number of subjects: 996
Study 9462188 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a median dose of 5 ppm for 72 hours
Number of subjects: 42
Study 9462188 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 42
Study 9462188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhaled nitric oxide)
Number of subjects: 42
Study 7875151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir plus GM‐CSF (1‐8 micrograms/kg daily subcutaneously)
Number of subjects: 53
Study 7875151 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir alone
Number of subjects: 53
Study 7875151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir plus GM‐CSF
Number of subjects: 53
Study 3344976 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60
Study 3344976 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study 29476940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 202
Study 29476940 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 202
Study 26847114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol for 24 hours
Number of subjects: 101
Study 26847114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 25594220 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope (Mil)
Number of subjects: 23
Study 25594220 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope Pentax‐AWS Airway Scope (AWS‐N)
Number of subjects: 23
Study 23084565 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg) followed by 300 IU rFSH in a GnRH antagonist protocol
Number of subjects: 43
Study 23084565 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol for poor responders (short agonist-hMG)
Number of subjects: 43
Study 20930611 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-paravertebral anesthetic (PPA) technique
Number of subjects: 40
Study 20930611 — intervention group
Group type: COMPARATOR
Intervention: Balanced general anesthesia (GA)
Number of subjects: 40
Study 18371596 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda water (100 mL)
Number of subjects: 95
Study 18371596 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 95
Study 16637756 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed emotion words
Number of subjects: 0
Study 16637756 — intervention group
Group type: COMPARATOR
Intervention: Satiated emotion words
Number of subjects: 0
Study 12792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarticular screw fixation
Number of subjects: 67
Study 12792338 — intervention group
Group type: COMPARATOR
Intervention: Posterior cervical wiring and halo-vest immobilization
Number of subjects: 67
Study 10802980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 58
Study 10802980 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 58
Study 10802980 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study 8659596 — intervention group
Group type: EXPERIMENTAL
Intervention: Videokeratoscopic analysis of the peripheral recipient cornea
Number of subjects: 16
Study 8659596 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative central corneal power
Number of subjects: 16
Study 1985364 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 169
Study 1985364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 6345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 103
Study 6345378 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 103
Study 6345378 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Verapamil
Number of subjects: 103
Study 31438268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 0
Study 30081337 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based drug prevention program #Tamojunto
Number of subjects: 5028
Study 30081337 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5028
Study 26856295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (GS)
Number of subjects: 20
Study 26856295 — intervention group
Group type: COMPARATOR
Intervention: Propofol (GP)
Number of subjects: 20
Study 23750966 — intervention group
Group type: EXPERIMENTAL
Intervention: Written text presented before speech
Number of subjects: 0
Study 23750966 — intervention group
Group type: COMPARATOR
Intervention: Written text presented after speech
Number of subjects: 0
Study 23750966 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological correspondence between text and speech
Number of subjects: 0
Study 22292487 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T)
Number of subjects: 245
Study 22292487 — intervention group
Group type: COMPARATOR
Intervention: Loteprednol etabonate 0.5% (LE)
Number of subjects: 245
Study 22292487 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin ophthalmic solution 0.3%
Number of subjects: 245
Study 22292487 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 245
Study 21060033 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 2046
Study 21060033 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 2046
Study 17984242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 24
Study 17984242 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 24
Study 17984242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 15178207 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 30
Study 15178207 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11432252 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thoracic artery graft
Number of subjects: 0
Study 11432252 — intervention group
Group type: COMPARATOR
Intervention: Venous grafts
Number of subjects: 0
Study 9895187 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture + placebo
Number of subjects: 270
Study 9895187 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 270
Study 9895187 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 270
Study 8299330 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 pints of Dioralyte (glucose and electrolyte solution)
Number of subjects: 197
Study 8299330 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 pints of half-strength Dioralyte
Number of subjects: 197
Study 8299330 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 pints of water
Number of subjects: 197
Study 8299330 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 pints of water
Number of subjects: 197
Study 8299330 — intervention group
Group type: EXPERIMENTAL
Intervention: free fluids
Number of subjects: 197
Study 2522117 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 14
Study 2522117 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 14
Study 7692934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic plus G-CSF mobilization
Number of subjects: 22
Study 7692934 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic mobilization
Number of subjects: 22
Study 631687 — intervention group
Group type: EXPERIMENTAL
Intervention: Special institutions for mentally abnormal offenders
Number of subjects: 348
Study 31536007 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT+MIT
Number of subjects: 34
Study 31536007 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 34
Study 27806647 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg slow-release L-cysteine
Number of subjects: 7
Study 27806647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 25805886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) program utilizing active-play video games (Xbox 360 Kinect) and traditional AE equipment for 12 weeks
Number of subjects: 33
Study 25805886 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric treatment (treatment as usual; TAU)
Number of subjects: 33
Study 23790994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced group (received narratives and peer support for CRC screening in online forums)
Number of subjects: 306
Study 23790994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced group
Number of subjects: 306
Study 23790994 — intervention group
Group type: COMPARATOR
Intervention: Basic group (received education only)
Number of subjects: 306
Study 21453351 — intervention group
Group type: EXPERIMENTAL
Intervention: α-blockers (tamsulosin or alfuzosin)
Number of subjects: 461
Study 21453351 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 461
Study 19148579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified MAID (5 cycles, doses 20-33% higher per cycle)
Number of subjects: 162
Study 19148579 — intervention group
Group type: COMPARATOR
Intervention: MAID (6 cycles: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine)
Number of subjects: 162
Study 19148579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified MAID
Number of subjects: 162
Study 19148579 — intervention group
Group type: COMPARATOR
Intervention: MAID
Number of subjects: 162
Study 17525497 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal ointments based on Georgian mineral waters (N1 - 'Achtala'; N2 - 'Sairme'; N3 - 'Tschaltubo'; N4 - 'Amagleba')
Number of subjects: 80
Study 17525497 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal ointments based on Georgian mineral waters
Number of subjects: 80
Study 14699371 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare
Number of subjects: 631
Study 14699371 — intervention group
Group type: EXPERIMENTAL
Intervention: Private Insurance
Number of subjects: 631
Study 14699371 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 631
Study 14699371 — intervention group
Group type: COMPARATOR
Intervention: Geographic Variation
Number of subjects: 631
Study 14699371 — intervention group
Group type: COMPARATOR
Intervention: Female Dermatologists
Number of subjects: 631
Study 14699371 — intervention group
Group type: COMPARATOR
Intervention: Low Concentration of Dermatologists
Number of subjects: 631
Study 11826727 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip force control measures in older adults
Number of subjects: 18
Study 11826727 — intervention group
Group type: COMPARATOR
Intervention: Grip force control measures in younger adults
Number of subjects: 18
Study 9505879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 222
Study 9505879 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 222
Study 9505879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily (excluding those who died within 30 days)
Number of subjects: 222
Study 9505879 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily (excluding those who died within 30 days)
Number of subjects: 222
Study 8116975 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (synthetic prostaglandin E1 analog)
Number of subjects: 100
Study 8116975 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid therapy
Number of subjects: 100
Study 8116975 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (control group)
Number of subjects: 100
Study 8116975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who refused to participate
Number of subjects: 100
Study 2980288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg/day)
Number of subjects: 9
Study 2980288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31885287 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based multidomain cognitive training program (RehaCom software), 15 weeks, twice a week, 1 hour per session
Number of subjects: 46
Study 31885287 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 46
Study 28086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exenatide-infusion
Number of subjects: 57
Study 28086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 57
Study 28086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 57
Study 28086201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 26235803 — intervention group
Group type: EXPERIMENTAL
Intervention: eTKVellipsoid
Number of subjects: 220
Study 26235803 — intervention group
Group type: EXPERIMENTAL
Intervention: eTKVPANK
Number of subjects: 220
Study 26235803 — intervention group
Group type: COMPARATOR
Intervention: mTKV
Number of subjects: 220
Study 23333929 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trans-uterine arterial chemotherapy (TUAC) with paclitaxel (60 mg/m² intravenously on days 1, 8, and 15) and cisplatin (70 mg/m² TUAC) repeated every 3 weeks for 3 cycles.
Number of subjects: 22
Study 23333929 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trans-uterine arterial chemotherapy (TUAC) followed by type III radical hysterectomy (RH).
Number of subjects: 22
Study 21471415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral component
Number of subjects: 40
Study 21471415 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium femoral component
Number of subjects: 40
Study 20016113 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% resistance exercise
Number of subjects: 68
Study 20016113 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% resistance exercise
Number of subjects: 68
Study 20016113 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% resistance exercise
Number of subjects: 68
Study 20016113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 68
Study 20016113 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 68
Study 20016113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 16750124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary advice on increasing physical activity during free time
Number of subjects: 0
Study 16750124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 15243988 — intervention group
Group type: EXPERIMENTAL
Intervention: DikoL program (n = 33)
Number of subjects: 106
Study 15243988 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 35)
Number of subjects: 106
Study 10992380 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral roots (15 Hz, 50% intensity, 5 seconds per minute for 30 minutes)
Number of subjects: 75
Study 10992380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 75
Study 10992380 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 75
Study 8796406 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational nitric oxide (NO) therapy, mean concentration 4.9 +/- 0.8 ppm
Number of subjects: 10
Study 8796406 — intervention group
Group type: COMPARATOR
Intervention: Control group (NO removal)
Number of subjects: 10
Study 1732342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg/day cyclosporine
Number of subjects: 217
Study 1732342 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg/day cyclosporine
Number of subjects: 217
Study 1732342 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day cyclosporine
Number of subjects: 217
Study 6433737 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic technique (NLA) using fentanyl 0.0025 mg/kg and droperidol 0.125 mg/kg (Thalamonal)
Number of subjects: 200
Study 6433737 — intervention group
Group type: COMPARATOR
Intervention: Halothane 1%
Number of subjects: 200
Study 29134517 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine 1 mg·kg‐1 (n=30)
Number of subjects: 59
Study 29134517 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo group, n=29)
Number of subjects: 59
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (cycling for 30 min at 55% of peak oxygen consumption) on day 1
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (cycling for 30 min at 55% of peak oxygen consumption) on day 2
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: First exercise session on day 1
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: First exercise session on day 2
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Second exercise session on day 1
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Second exercise session on day 2
Number of subjects: 8
Study 28586529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-individual difference in change in plasma glucose between testing days after first exercise session
Number of subjects: 8